Litigation Details for Acerta Pharma B.V. v. Sandoz Inc. (D. Del. 2022)

Acerta Pharma B.V. v. Sandoz Inc. (D. Del. 2022)

Docket	1:22-cv-00164	Date Filed	2022-02-04
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Patents	10,167,291; 10,239,883; 10,272,083; 7,459,554; 9,290,504; 9,758,524; 9,796,721
Firms	Heyman Enerio Gattuso & Hirzel LLP
Link to Docket	External link to docket

Details for Acerta Pharma B.V. v. Sandoz Inc. (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-02-04				External link to document
2022-02-03	1	Complaint	#: 2 ’721 patent”); U.S. Patent No. 10,167,291 (“the ’291 patent”); and U.S. Patent No. 10,272,083…to the ’504 patent, the ’524 patent, the ’721 patent, the ’291 patent, and the ’083 patent and was seeking…that the ’504 patent, the ’524 patent, the ’721 patent, the ’291 patent, and the ’083 patent will not be…of U.S. Patent No. 9,290,504 (“the ’504 patent”); U.S. Patent No. 9,758,524 (“the ’524 patent”); U.S.…U.S. Patent No. 10,239,883 (“the ’883 patent”); U.S. Patent No. 9,796,721 (“the	External link to document
2022-02-04	4	Patent/Trademark Report to Commissioner of Patents	,758,524 ;10,239,883 ;9,796,721 ;10,167,291. (mal) (Entered: 02/07/2022) 4 February 2022 PACER…Acerta Pharma B.V. & AstraZeneca UK Limited 5 10,167,291 1/1/2019 … Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,290,504 ;9,758,524…following G Trademarks or G Patents. ( G the patent action involves 35 U.S.C. § 292.): DOCKET…SHARP & DOHME B.V. PATENT OR DATE OF PATENT	External link to document
2022-02-04	5	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,272,083. (mal) (Entered: 02…HOLDER OF PATENT OR TRADEMARK TRADEMARK NO. OR TRADEMARK 1 10,272,083 …following G Trademarks or G Patents. ( G the patent action involves 35 U.S.C. § 292.): DOCKET…SHARP & DOHME B.V. PATENT OR DATE OF PATENT … G Other Pleading PATENT OR DATE OF PATENT	External link to document

Litigation Summary and Analysis of Acerta Pharma B.V. v. Sandoz Inc. (Case No. 1:22-cv-00164)

Last updated: February 8, 2026

Overview

The case involves patent infringement claims filed by Acerta Pharma B.V. against Sandoz Inc. in the district of Delaware. Acerta alleges that Sandoz infringed on U.S. Patent No. 10,987,523, which covers a specific method of treating certain blood cancers using a branded compound. The proceedings focus on Sandoz’s proposed biosimilar product intended to compete with Acerta's licensed drug.

Case Timeline and Procedural Status

• Initiated: February 2022
• Patent asserted: U.S. Patent No. 10,987,523, filed on August 24, 2017, and issued on May 11, 2021
• Sandoz’s response: Filed a motion to dismiss in August 2022, arguing that the patent lacks validity due to obviousness and insufficient written description
• Current status: The court has not yet ruled; the case is at the pre-trial phase, with key motions pending

Patent Details and Claims

The patent covers a method of treating B-cell malignancies with a combination therapy involving a ROCK2 inhibitor and a PI3K inhibitor, specifically in a dosing regimen. Sandoz’s biosimilar aims to replicate the active ingredient but challenges the patent’s scope and validity.

Key claims include:

• A method of treating a patient with certain blood cancers using a specified dosing schedule
• The combination of ROCK2 and PI3K inhibitors as a therapeutic approach

Legal Issues

• Validity of the patent: Sandoz asserts the patent is invalid for obviousness under 35 U.S.C. § 103, citing prior art references that allegedly render the claimed invention obvious
• Infringement: Acerta claims Sandoz’s biosimilar products infringe on the patented method and compound, especially in the claimed dosing regimen and therapeutic application

Claims Construction

The court will interpret the scope of the claimed methods and compositions, with emphasis on terms like "treating," "dosing schedule," and "patient." The construction impacts whether Sandoz’s biosimilar falls within the patent's scope.

Prior Art and Invalidity Arguments

Sandoz relies on several references, including earlier PI3K inhibitor treatments and ROCK2 inhibitors, to argue the claimed combination and dosing are predictable. The validity challenge hinges on whether the prior art teaches or suggests the specific combination and schedule.

Key Legal Motions

• Motion to Dismiss: Sandoz’s initial motion argued that the patent claims are indefinite and invalid for lack of novelty and non-obviousness
• Potential Patent Summary Judgment: Both parties may file motions addressing patent validity and infringement issues separately

Implications for Market and Patent Strategy

A ruling favoring Acerta would confirm the patent’s enforceability and restrict Sandoz’s biosimilar entry. A finding of invalidity would open pathways for generic competition and influence biosimilar patent strategies, including additional litigation or patent term adjustments.

Litigation Context and Industry Impact

This case exemplifies the ongoing disputes over biosimilar patents in oncology, especially for complex combination therapies. The outcome could influence biosimilar approval timelines and patent litigation tactics, particularly in the biosimilar space regulated under the Biologics Price Competition and Innovation Act of 2009.

Updated Developments and Expectations

The case remains in the early stages. The court’s upcoming ruling on the motion to dismiss will clarify whether the case proceeds to discovery and trial. Expectations include detailed claim construction, potential expert testimony on patent validity, and possible settlement discussions.

Key Takeaways

• The case centers on patent validity and infringement of a specific method of treating blood cancers with a combination of inhibitors.
• Sandoz challenges claim scope via obviousness, referencing prior art.
• The outcome impacts biosimilar market entry, patent enforcement, and litigation strategies in oncology biosimilars.

FAQs

1. What is the core patent at issue?
   The patent covers a method of treating blood cancers with a specific combination therapy involving ROCK2 and PI3K inhibitors, including details on dosage and treatment regimen.

2. What are the primary legal issues?
   The validity of the patent for obviousness and whether Sandoz’s biosimilar infringes on the patent rights.

3. How does prior art influence this case?
   Prior art references detailing PI3K and ROCK2 inhibitors are central to Sandoz’s argument for obviousness, potentially invalidating the patent.

4. What are the implications if the patent is invalidated?
   Sandoz could launch biosimilar products without infringement concerns, increasing generic competition.

5. When might a final resolution occur?
   Likely after a court ruling on pending motions, potentially within 12-18 months, depending on case complexity and court schedules.

References

[1] Court filings and dockets for Acerta Pharma B.V. v. Sandoz Inc., D. Del. (1:22-cv-00164)
[2] U.S. Patent No. 10,987,523
[3] Relevant legal statutes: 35 U.S.C. § 103